The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure ...

Gilead (GILD) announced The New England Journal of Medicine, or NEJM, published the full results from the company’s pivotal ...

Gilead and Aelix first teamed up in 2018 for a clinical research collaboration agreement to investigate the vaccine.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results ...

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) on November 25 and set a price target ...

Women – especially teen girls and young women living in sub-Saharan Africa – are disproportionately impacted by <a ...

Six years after first allying with Aelix Therapeutics to test the Spanish biotech’s HTI vaccine for HIV, Gilead Sciences has ...

Sac-TMT, also known as SKB264 or MK-2870, represents the first asset in Kelun’s multitarget, multibillion-dollar ADC ...

Zacks Research increased their FY2024 earnings per share (EPS) estimates for Gilead Sciences in a note issued to investors on ...

Gilead Sciences demonstrated positive momentum on the NASDAQ, with shares climbing 0.6 percent to $91.88. This upward trajectory is primarily attributed to groundbreaking results from clinical trials ...

Spanish HIV focused immunotherapies company AELIX Therapeutics, a spin-off of IrisCaixa, has announced the acquisition of its ...